6533b7d5fe1ef96bd1265028
RESEARCH PRODUCT
LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
M. LiKaoru KondoMing LeiT. LiuLucjan WyrwiczMichael SchenkerMarcelo GarridoTomasz SkoczylasL. ShenJaffer A. AjaniYelena Y. JanjigianValerie PoulartA. Campos BragagnoliMarkus MoehlerDana CullenK. ShitaraKensei YamaguchiMustapha TehfePamela SalmanPatricio Eduardo Yanezsubject
Oncologymedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentFirst lineEsophageal adenocarcinomaCancerHematologyAdvanced gastric cancerGastroesophageal Junctionmedicine.diseaseOncologyInternal medicinemedicineNivolumabbusinessyear | journal | country | edition | language |
---|---|---|---|---|
2020-09-01 | Annals of Oncology |